LTRN icon

Lantern Pharma

4.57 USD
+0.06
1.33%
At close Aug 25, 4:00 PM EDT
After hours
4.57
+0.00
0.00%
1 day
1.33%
5 days
3.39%
1 month
7.78%
3 months
57.59%
6 months
15.11%
Year to date
38.48%
1 year
-1.72%
5 years
-73.89%
10 years
-69.43%
 

About: Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.

Employees: 24

0
Funds holding %
of 7,429 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

800% more call options, than puts

Call options by funds: $108K | Put options by funds: $12K

100% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 5

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

6% more funds holding

Funds holding: 31 [Q1] → 33 (+2) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

1.68% less ownership

Funds ownership: 22.46% [Q1] → 20.78% (-1.68%) [Q2]

18% less capital invested

Capital invested by funds: $8.59M [Q1] → $7.08M (-$1.51M) [Q2]

Research analyst outlook

We haven’t received any recent analyst ratings for LTRN.

Financial journalist opinion

Based on 5 articles about LTRN published over the past 30 days

Neutral
Business Wire
1 week ago
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates
DALLAS--(BUSINESS WIRE)--Q2 2025 Financial Results & Business Updates.
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates
Neutral
Business Wire
2 weeks ago
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
DALLAS--(BUSINESS WIRE)--Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc. (NASDAQ: LTRN), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase Ib/2a clinical trial to evaluate STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (GBM) at first progression. The planned Phase Ib/2a clinical trial (IND 178511) is designed to investigate the safety, to.
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
Neutral
Business Wire
3 weeks ago
Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence company transforming oncology drug discovery and development, today announced the public release of its AI module for predicting blood-brain barrier (BBB) permeability of small molecules with unprecedented accuracy and scalability – predictBBB.ai™. This critical advancement addresses one of pharmaceutical development's most persistent challenges—that only 2-6% of small-molecule drugs can successful.
Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™
Neutral
Business Wire
3 weeks ago
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300
DALLAS--(BUSINESS WIRE)--Harmonic Trial - Japan Cohort Completion.
Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300
Neutral
Business Wire
4 weeks ago
Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors
DALLAS--(BUSINESS WIRE)--Dr. Lee Schalop Joins Lantern Pharma BOD.
Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors
Neutral
Business Wire
1 month ago
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to systematically transform drug discovery paradigms, today announces that a heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase 1 clinical trial of LP-284. This represents the first complete response observed.
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
Neutral
Business Wire
1 month ago
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to accelerate drug discovery, today announced that the European Patent Office (EPO) has issued a notice of allowance for a composition of matter patent covering its drug candidate LP-284. This patent, expected to be granted in the coming months with exclusivity through early 2039, strengthens Lantern's global intellectual property.
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy
Neutral
Business Wire
1 month ago
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the launch of an innovative AI-powered module within its proprietary RADR® platform, designed to predict the activity and efficacy of combination regimens involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) in clinical cancer treatment. With the global market for combination cancer therapi.
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
Neutral
Business Wire
2 months ago
Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announces remarkable clinical observations for a patient in Lantern's Phase 2 HARMONIC™ clinical trial. A 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) has achieved a durable complete response in their target cancer lesions following treatment with LP-300 in combination with standard-o.
Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years
Neutral
Business Wire
2 months ago
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials
DALLAS--(BUSINESS WIRE)--ATRT data presented at SNO Pediatric 2025.
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials
Charts implemented using Lightweight Charts™